Headline
The latest stories from AHA Today.
AHA leaders tomorrow will participate in a series of panels during the International Hospital Federation’s 48th annual World Hospital Congress in Geneva.
The Senate Nov. 9 took a critical first step toward ending the government shutdown as seven Democrats and Sen. Angus King, I-Maine, joined Republicans to advance a government funding agreement.
Senate negotiations on a potential funding deal to end the record-long government shutdown are ongoing, and the chamber is likely to continue working through this weekend in hopes of nearing a resolution.
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned with those paid in other countries, known as most-favored-nation pricing.
The AHA Nov. 7 released “Integrating Behavioral Health into Pediatric Care: Hospital-led Solutions to a Growing Crisis,” featuring five case studies on how the integration of behavioral health care into a variety of care settings means clinicians can recognize symptoms early, provide immediate…
The AHA will host a webinar Nov. 13 at 2 p.m. ET that will explore scalable, community-driven strategies that support patients and improve outcomes during the vital transition period from hospital to home.
Caitlin Gillooley, AHA director of quality and behavioral health policy, and Evelyn Ivy Mwangi, M.D., Luminis Health Anne Arundel Medical Center geriatric hospitalist, will discuss the Centers for Medicare & Medicaid Services’ Age-Friendly Hospital Measure and Luminis Health’s success in…
All 50 states have applied for the Rural Health Transformation Program, the Centers for Medicare & Medicaid Services announced today.
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed nations, known as the most-favored-nation price.
A Health Affairs study published Nov. 3 examined an increase in states banning prior authorizations in private insurance plans for opioid use disorder medications.